Tumour measurements on imaging for clinical trial: A national picture of service provision [0.03%]
影像学肿瘤测量在临床试验中的应用：一项对服务提供的全国性调查
Georgina Hopkinson,Jonathan Taylor,Jonathan Wadsley et al.
Georgina Hopkinson et al.
Background: Radiological response evaluation metrics such as RECIST 1.1 inform critical endpoints in oncology trials. The UK was the 6th highest recruiter into oncology trials worldwide between 1999 and 2022, with almost ...
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers [0.03%]
PD-0325901与crizotinib联用在晚期实体瘤患者中的Ia期研究
Peter Gallagher,Christian Rolfo,Elena Elez et al.
Peter Gallagher et al.
Background: Single-agent MEK1/2 inhibition has been disappointing in clinical trials targeting RAS mutant (MT) cancers, probably due to upstream receptor activation, resulting in resistance. We previously found that dual ...
A novel multigene panel (Sig27) robustly predicts poor prognosis of renal cell carcinoma via high-level associations with immunosuppressive features [0.03%]
一个新的多基因检测小组(Sig27)通过与免疫抑制特征的高水平关联有力地预测肾细胞癌的不良预后
Ying Dong,Bobby Shayegan,Yingying Su et al.
Ying Dong et al.
Background: We investigated a 27-gene panel (Sig27), derived from prostate cancer, for risk stratification of RCC (clear cell RCC/ccRCC, papillary RCC/pRCC, and chromophobe RCC/chRCC). ...
Epidemiology of multimorbidity in childhood cancer survivors: a matched cohort study of inpatient hospitalisations in Western Australia [0.03%]
儿童癌症幸存者多重病症的流行病学：澳大利亚西部住院匹配队列研究
Tasnim Abdalla,Jeneva L Ohan,Angela Ives et al.
Tasnim Abdalla et al.
Background: Childhood cancer survivors (CCS) experience an elevated burden of health complications, underscoring the importance of understanding the patterns of multimorbidity to guide the management of survivors with com...
Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review [0.03%]
卵巢癌中PARP抑制剂疗效的预测生物标志物的最新系统评价
Ying-Wen Wang,Isaac Allen,Gabriel Funingana et al.
Ying-Wen Wang et al.
Background: PARP inhibitors are effective in treating ovarian cancer, especially for BRCA1/2 pathogenic variant carriers and those with HRD (homologous recombination deficiency). Concerns over toxicity and costs have led ...
Deep-learning enabled combined measurement of tumour cell density and tumour infiltrating lymphocyte density as a prognostic biomarker in colorectal cancer [0.03%]
深度学习使肿瘤细胞密度和肿瘤浸润淋巴细胞密度的联合测量成为结肠癌预后生物标志物
Alice C Westwood,Benjamin I Wilson,Jon Laye et al.
Alice C Westwood et al.
Background: Within the colorectal cancer (CRC) tumour microenvironment, tumour infiltrating lymphocytes (TILs) and tumour cell density (TCD) are recognised prognostic markers. Measurement of TILs and TCD using deep-learni...
Health inequalities in hepatocellular carcinoma surveillance, diagnosis, treatment, and survival in the United Kingdom: a scoping review [0.03%]
英国在肝细胞癌的监测、诊断、治疗和生存方面的健康不平等：一项范围综述
Christopher Mysko,Stephanie Landi,Huw Purssell et al.
Christopher Mysko et al.
Background: Hepatocellular carcinoma (HCC) remains a deadly cancer in the UK despite advancements in curative therapies. Societal conditions and health inequalities influence the development of chronic liver disease and o...
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours [0.03%]
CITRINO：抗癌 Lag-3 抗体 Encelimab 单药或与抗 PD-1 抗体 Dostarlimab 联合用于晚期/转移性实体瘤患者的 1 期剂量递增研究
J Randolph Hecht,Jean-Marie Michot,David Bajor et al.
J Randolph Hecht et al.
Background: Dual programmed cell death protein (ligand)-1 (PD-[L]1) and lymphocyte-activation gene-3 (LAG-3) blockade has demonstrated improved anti-tumour response in some advanced solid tumours. CITRINO, a two-part, Pha...
Activation of FGFR genes by genetic and epigenetic alterations in uterine leiomyomas [0.03%]
FGFR基因的遗传和表观遗传改变在子宫肌瘤中的激活作用
Vilja Jokinen,Aurora Taira,Åsa Kolterud et al.
Vilja Jokinen et al.
Background: Fibroblast growth factor 1-4 (FGFR1-4) are well-known oncogenic drivers in many cancer types. Here, we studied the role of FGFRs in uterine leiomyoma (UL) that is a benign neoplasm arising from the myometrium ...
Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance [0.03%]
打破障碍：我们需要多学科的方法来攻克癌症药物抗性问题
James Ingham,Jia-Ling Ruan,Matthew A Coelho
James Ingham
Most cancer-related deaths result from drug-resistant disease(1,2). However, cancer drug resistance is not a primary focus in drug development. Effectively mitigating and treating drug-resistant cancer will require advancements in multiple ...